Novo Nordisk A/s

Schering Aktiengesellschaft

Other

Novozymes A/s

Novo Nordisk Healthcare Ag

Novo Nordiskals

Novo Nordick A/s

Norozymes A/s

Jens Breinholt

Ida Hilden

Berit Olsen Krogh

Claus Crone Fuglsang

Lisbeth Bech

Anders Ohmann

Ole Hvilsted Olsen

Georg W Jensen

Jes Thorn Clausen

Mikael Kofod-Hansen

Anthony Murray

Lars Christian Petersen

Soren Flensted Lassen

Peter Faarup

Peter Rahbek Ostergaard

Thorsten Blume

Helle Heibroch Petersen

Ruby Ione Nielsen

Brian Lauritzen

Lene Nonboe Andersen

Markus Sakari Kauppinen

Stephan Christgau

Lene Venke Kofod

Hans Sejr Olsen

Ruby Ilum Nielsen

Henrik Oestergaard

Prafull S Gandhi

So Slashedren Lassen

Brit Binow Soerensen

Helle Demuth

Peter Rahbet Stergaard

Henrik Dalbo Slashedge

Lene Lange

Bernd Peschke

Susanne Nedergaard Grell

Mette Dahl Andersen

Jais Rose Bjelke

Thomas Egebjerg

Christine Bruun Schiødt

Peter Thygesen

Frederik Christian Grønvald

Henrlk Dalbo Slashedge

Birgitte Rassing Romer

Frederick Christian Gr&oslash;nvald

Frederick Christian Grønvald

Brit Binow Sørensen

Leif Nørskov-Lauritsen

The invention relates to a bispecific antibody comprising a first antigen-binding site capable of binding Factor VII(a) and a second antigen-binding site capable of binding TLT-1, pharmaceutical formulations comprising such bispecific antibodies and uses thereof.

Factor VII (FVII(a))/TREM-like transcript 1 (TLT-1) bispecific antibodies

Bispecific antibodies

The application discloses bispecific TFPI antibodies that are capable of specifically and simultaneously binding two epitopes within TFPI (1-161). Such bispecific antibodies strongly enhance thrombin generation by neutralising TFPI, even where the concentration of TFPI is elevated. Bispecific antibodies of the invention or compositions comprising them may be used for the treatment of subjects with a coagulopathy.

Antibodies capable of binding two epitopes on tissue factor pathway inhibitor (1-161)

Described are procoagulant proteins which may, for example, be fusion proteins or chemical conjugates; methods of producing procoagulant proteins; polynucleotides that encode fusion proteins and cells that expresses them. Furthermore, described are procoagulant proteins for use as a medicament. Individuals that have a coagulopathy, such as haemophilia A and B with or without inhibitors, may be treated with such procoagulant proteins.

Coagulation factor-targeting to TREM-like transcript 1 (TLT-1) on activated platelets

The application discloses a combination of two monospecific TFPI antibodies, wherein one antibody is capable of specifically binding TFPI (1-181) and the other antibody is capable of specifically binding TFPI (182-276), as well as bispecific anti-TFPI antibodies derived from two such monospecific antibodies. Both the combination of the two monospecific antibodies and the bispecific antibody strongly enhance thrombin generation by neutralising full length TFPI&#x3b1;, even where the concentration of TFPI is abnormally elevated.

Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor

The current invention relates to procoagulant fusion proteins, polynucleotides that encode said fusion proteins and cells that expresses said fusion proteins. Furthermore, the current invention relates to fusion proteins for use as a medicament. Individuals that have a coagulopathy, such as haemophilia A and B with or without inhibitors, may be treated with fusions proteins of the current invention.

Targeting tissue factor to activated platelets

The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy.

Antibodies against tissue factor pathway inhibitor

Methods of treating coagulopathies using antibodies against tissue factor pathway inhibitor

The present invention relates to stable growth hormone (GH) compounds, which through the introduction of cysteine residues have disulphide bridges, which make the compounds resistant to proteolytic degradation.

Stable growth hormone compounds resistant to proteolytic degradation

The present invention relates to isolated polypeptides having phytase activity, the corresponding cloned DNA sequences, a process for preparing such polypeptides, and the use thereof for a number of industrial applications. In particular, the invention relates to phytases derived from the phyllum Basidiomycota, phytases of certain consensus sequences and fungal 6-phytases.

Phytase polypeptides

Certain novel sterol derivatives can be used for regulating the meiosis in oocytes and in male germ cells.

Meiosis regulating compounds

Growing community of inventors

Bagsvaerd, Denmark

Jens Breinholt